Table 3.

Neoadjuvant treatment-related adverse events

	Any grade	Grades 1–2	Grade 3	Grade 4
Neutropenia	14 (60.9)	5 (21.7)	5 (21.7)	4 (17.4)
Leukopenia	14 (60.9)	12 (52.2)	1 (4.3)	1 (4.3)
Alopecia	19 (82.6)	19 (82.6)	0	0
Asthenia	15 (65.2)	15 (65.2)	0	0
Rash	14 (60.9)	14 (60.9)	0	0
Anemia	13 (56.5)	13 (56.5)	0	0
Alanine aminotransferase increased	10 (43.5)	10 (43.5)	0	0
Aspartate aminotransferase increased	8 (34.8)	8 (34.8)	0	0
Reactive cutaneous capillary endothelial proliferation	9 (39.1)	9 (39.1)	0	0
Hyperbilirubinemia	8 (34.8)	8 (34.8)	0	0
Decreased appetite	8 (34.8)	8 (34.8)	0	0
Thrombocytopenia	7 (30.4)	7 (30.4)	0	0
Vomiting	5 (21.7)	5 (21.7)	0	0
Oral mucositis	4 (17.4)	4 (17.4)	0	0
Nausea	3 (13.0)	3 (13.0)	0	0
Diarrhea	3 (13.0)	3 (13.0)	0	0
Constipation	3 (13.0)	3 (13.0)	0	0
Edema	2 (8.7)	2 (8.7)	0	0
Fever	2 (8.7)	2 (8.7)	0	0
Hyperthyroidism	1 (4.3)	1 (4.3)	0	0
Arthralgia	1 (4.3)	1 (4.3)	0	0
Peripheral sensory neuropathy	1 (4.3)	1 (4.3)	0	0

Data are presented as n (%).

Adverse events were graded according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events, version 5.0.